Arizona Clinical Research Center | Tucson, AZ

Research site

(Unclaimed)

Location

1825 N Kolb Road, Tucson, Arizona, United States of America

Site insights

Top conditions

Top treatments

Gemcitabine

Carboplatin

Dexamethasone

Paclitaxel

Leucovorin

Pixantrone

Oxaliplatin

IPI-549

Bevacizumab

Elotuzumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 73 total trials

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting

Non-small Cell Lung Cancer (NSCLC)

Drug: Tiragolumab

Drug: Durvalumab

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4)

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), p...

Active, not recruiting

Non Small Cell Lung Cancer Metastatic

Sensitizing EGFR Gene Mutation

Drug: Zimberelimab

Drug: Etrumadenant

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REG...

Enrolling

Advanced Non-Small Cell Lung Cancer

Drug: cemiplimab

Drug: Placebo

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemothera...

Enrolling

Non-small Cell Lung Cancer

Drug: Pemetrexed

Drug: fianlimab

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (ARC-9)

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in partic...

Active, not recruiting

Metastatic Colorectal Cancer

Drug: Bevacizumab

Drug: Zimberelimab

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol inv...

Active, not recruiting

Multiple Myeloma

Drug: Pomalidomide

Drug: Dexamethasone

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology...

Active, not recruiting

Breast Cancer

Renal Cell Carcinoma

Drug: nab-paclitaxel

Drug: Bevacizumab

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patien...

Enrolling

Metastatic Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

Drug: Pembrolizumab

Drug: Adagrasib